Dermata Therapeutics, Inc. (DRMAW) Financials
DRMAW Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 5.3 million | 1.8 million |
| March 31, 2026 | 7.5 million | 1.1 million |
| Dec. 31, 2025 | 7.9 million | 1.6 million |
| Sept. 30, 2025 | 5.1 million | 1.1 million |
DRMAW Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | -2.5 million | 41780 |
| March 31, 2026 | -2.5 million | 43278 |
| Dec. 31, 2025 | -1.3 million | 29469 |
| Sept. 30, 2025 | -1.8 million | 37841 |
DRMAW Net Income
No data available :(
DRMAW Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 4.4 million | - | - |
| March 31, 2026 | 6.9 million | - | - |
| Dec. 31, 2025 | 7.5 million | - | - |
| Sept. 30, 2025 | 4.7 million | - | - |
DRMAW Shares Outstanding
DRMAW Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | 110667 | 212563 | 428966 | - |
| March 31, 2026 | - | 383724 | 1.3 million | 206333 |
| Dec. 31, 2025 | 3 | 526620 | 1.4 million | - |
| Sept. 30, 2025 | 5 | 504387 | 783344 | 472940 |
DRMAW Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | - | - |
| March 31, 2026 | - | - |
| Dec. 31, 2025 | - | - |
| Sept. 30, 2025 | - | - |
DRMAW
Price: $0
52 week price:
Earnings Per Share: -2.16 USD
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Volume: 203
Market Capitalization: 5112